Phase 2 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 75 years old
- People diagnosed with a specific type of ovarian, fallopian tube, or peritoneal cancer called high-grade serous cancer, confirmed by biopsy or tissue testing
- People whose cancer was assessed by an initial keyhole surgery (laparoscopy) that confirmed the cancer type, how far it had spread, and that it could not be fully removed at that stage
- People with cancer at a certain stage of spread (Stage III B-C or Stage IVA with only a small amount of fluid around the lungs — less than 3 cm thick on a chest scan)
- People who have had successful surgery to remove all visible cancer after chemotherapy (called interval cytoreduction surgery)
- People who have received 3 to 4 rounds of a specific chemotherapy combination (Carboplatin and Paclitaxel) before surgery
- People whose surgery took place between 4 and 8 weeks after their last chemotherapy treatment
- People whose blood counts meet certain minimum levels: haemoglobin at least 10 g/dL, white blood cells and platelets within acceptable ranges
- People whose liver function tests are within acceptable limits
- People whose kidneys are functioning well enough (confirmed by a specific calculation method called MDRD)
- People who have signed an informed consent form before any trial procedures begin
- People who are part of the French social security system or an equivalent scheme
Who may not be able to join:
- People whose general health or ability to function day-to-day is significantly reduced (rated 2 or higher on the WHO performance scale)
- People with Stage IVB cancer, or Stage IVA with a larger amount of fluid around the lungs (more than 3 cm thick on a chest scan)
- People with reduced kidney function below the required level (confirmed by the MDRD method)
- People for whom major surgery or a heated chemotherapy procedure (HIPEC) would be medically unsafe, or who have a known allergy to any of the treatment components
- People with significant liver problems
- People with another serious or life-threatening illness
- People with heart or breathing conditions that would make the high fluid levels used during HIPEC unsafe
- People who have previously been treated with heated chemotherapy (chemo-hyperthermia) for ovarian cancer
- People with a history of another cancer within the past five years, except for certain limited skin cancers or early-stage cervical changes that have not returned
- People with a severe untreated infection
- People experiencing significant nerve damage or numbness in the hands or feet (peripheral neuropathy grade 2 or higher) at the time of joining
- People for whom regular follow-up appointments would not be possible due to psychological, family, social, or geographic reasons
- People who are pregnant or breastfeeding
- People who are under legal guardianship or a court-appointed protection order
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Philippe ROUANET, MD, Institut Régional du Cancer de Montpellier (ICM)
Phone: 0467613102
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The success of the combination of HIPEC and IPC assessed by chemotherapy administration after surgery; The success of HIPEC and IPC combination assessed by surveillance safety
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.